1.43

2.05% -0.03

Pre-market: 1.45 0.02 +1.40%

Inovio Pharmaceuticals Inc (INO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Inovio Pharmaceuticals Inc stock is traded at $1.43, with a volume of 8.01M. It is down -2.05% in the last 24 hours and up +34.91% over the past month. Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Previous Close:

$1.46

Open:

$1.63

24h Volume:

8.01M

Relative Volume:

3.76

Market Cap:

$116.68M

Revenue:

$65,300

Net Income/Loss:

$-84.95M

P/E Ratio:

-0.7397

EPS:

-1.9332

Net Cash Flow:

$-88.92M

1W Performance:

+25.44%

1M Performance:

+34.91%

6M Performance:

-28.50%

1Y Performance:

-20.56%

1-Day Range:

$1.39

$1.635

1-Week Range:

$1.13

$1.79

52-Week Range:

$1.03

$2.9789

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name

Inovio Pharmaceuticals Inc

Sector

Healthcare (1110)

Industry

Biotechnology (619)

Phone

(858) 410-3134

Address

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Employee

112

Twitter

@inoviopharma

Next Earnings Date

2026-05-13

Latest SEC Filings

INO's Discussions on Twitter

Compare INO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INO Inovio Pharmaceuticals Inc	1.43	119.12M	65,300	-84.95M	-88.92M	-1.9332
VRTX Vertex Pharmaceuticals Inc	435.17	109.09B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	712.77	74.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	813.28	48.64B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	284.84	39.39B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	310.75	32.38B	5.36B	287.73M	924.18M	2.5229

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-09-25	Initiated	Piper Sandler	Overweight
May-14-24	Initiated	Stephens	Overweight
Jan-25-24	Upgrade	Oppenheimer	Perform → Outperform
Nov-09-22	Downgrade	Maxim Group	Buy → Hold
Nov-01-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-19-22	Resumed	RBC Capital Mkts	Sector Perform
May-11-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral
Dec-29-21	Resumed	Jefferies	Hold
Sep-10-21	Downgrade	BofA Securities	Neutral → Underperform
Jun-24-21	Initiated	Jefferies	Hold
Mar-23-21	Initiated	BofA Securities	Neutral
Feb-12-21	Initiated	Oppenheimer	Outperform
Nov-17-20	Downgrade	ROTH Capital	Neutral → Sell
Nov-10-20	Upgrade	ROTH Capital	Sell → Neutral
Sep-28-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-28-20	Upgrade	Maxim Group	Hold → Buy
Jul-01-20	Downgrade	Maxim Group	Buy → Hold
Jul-01-20	Downgrade	ROTH Capital	Neutral → Sell
Jun-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-20	Downgrade	Stifel	Buy → Hold
May-21-20	Initiated	The Benchmark Company	Buy
Apr-30-20	Downgrade	ROTH Capital	Buy → Neutral
Mar-13-20	Downgrade	Piper Sandler	Overweight → Neutral
Mar-13-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-19-19	Initiated	ROTH Capital	Buy
Feb-15-18	Reiterated	Maxim Group	Buy
Oct-18-17	Initiated	RBC Capital Mkts	Outperform
Sep-06-17	Initiated	Citigroup	Buy
Jun-08-17	Upgrade	Piper Jaffray	Neutral → Overweight
May-24-17	Reiterated	Maxim Group	Buy
Mar-16-17	Upgrade	Maxim Group	Hold → Buy
Mar-16-17	Downgrade	Piper Jaffray	Overweight → Neutral

View All

Inovio Pharmaceuticals Inc Stock (INO) Latest News

May 11, 2026

Inovio Pharmaceuticals Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView

May 11, 2026

Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone? - The Motley Fool

May 11, 2026

DPROT platform could enable sustained protein production for Hemophilia A, INOVIO Pharmaceuticals contends - Traders Union

May 11, 2026

Is Inovio (INO) Turning Fresh DNA Medicine Data Into a More Coherent Investment Story? - Sahm

May 11, 2026

May 10, 2026

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

May 08, 2026

Inovio Pharmaceuticals stock (US45773H2013): Earnings preview and DNA?medicine pipeline in focus - AD HOC NEWS

May 08, 2026

INO Stock Steadies Ahead Of Q1 2026 Earnings Catalyst - timothysykes.com

May 08, 2026

INO Stock Grinds Higher As Traders Eye Q1 2026 Catalyst - StocksToTrade

May 08, 2026

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults - Quantisnow

May 08, 2026

Two INOVIO studies head to May medical meetings in Boston, Chicago - Stock Titan

May 08, 2026

INOVIO to Participate in Upcoming Scientific Conferences - Barchart.com

May 08, 2026

Salt Lake City Topic INOVIO PHARMACEUTICALS, INC. | News, Weather, Sports, Breaking News - KMYU

May 08, 2026

INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits

May 08, 2026

Earnings Preview: INO to Report Financial Results Post-market on May 13 - Moomoo

May 08, 2026

May 07, 2026

RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y - The Globe and Mail

May 07, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

May 07, 2026

INO Technical Analysis | Trend, Signals & Chart Patterns | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - ChartMill

May 07, 2026

May 06, 2026

FMR LLC holds 9.34M shares in Inovio (NYSE: INO) — 13.5% reported - Stock Titan

May 06, 2026

May 05, 2026